TY  - JOUR
AB  - Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous disease regarding its pathophysiology and clinical outcomes. Two novel studies suggest that different clusters of people with MASLD exist, explaining part of this heterogeneity. These findings and future research applying data dimensionality reduction approaches might be beneficial for implementing precision medicine in MASLD.
AU  - Stefan, N.
AU  - Targher, G.*
C1  - 73538
C2  - 57095
CY  - Heidelberger Platz 3, Berlin, 14197, Germany
SP  - 226–227
TI  - Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine.
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 22
PB  - Nature Portfolio
PY  - 2025
SN  - 1759-5045
ER  - 

TY  - JOUR
AB  - Steatotic liver disease has emerged as an important risk factor for cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease. Successful treatment of steatotic liver disease might also be effective in preventing these cardiometabolic diseases.
AU  - Stefan, N.
AU  - Lonardo, A.*
AU  - Targher, G.*
C1  - 68942
C2  - 54993
CY  - Heidelberger Platz 3, Berlin, 14197, Germany
TI  - Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases.
JO  - Nat. Rev. Gastroenterol. Hepatol.
PB  - Nature Portfolio
PY  - 2023
SN  - 1759-5045
ER  - 

TY  - JOUR
AB  - Owing to advances in genomics that enable differentiation of molecular aetiologies, patients with monogenic inflammatory bowel disease (mIBD) potentially have access to genotype-guided precision medicine. In this Expert Recommendation, we review the therapeutic research landscape of mIBD, the reported response to therapies, the medication-related risks and systematic bias in reporting. The mIBD field is characterized by the absence of randomized controlled trials and is dominated by retrospective observational data based on case series and case reports. More than 25 off-label therapeutics (including small-molecule inhibitors and biologics) as well as cellular therapies (including haematopoietic stem cell transplantation and gene therapy) have been reported. Heterogeneous reporting of outcomes impedes the generation of robust therapeutic evidence as the basis for clinical decision making in mIBD. We discuss therapeutic goals in mIBD and recommend standardized reporting (mIBD REPORT (monogenic Inflammatory Bowel Disease Report Extended Phenotype and Outcome of Treatments) standards) to stratify patients according to a genetic diagnosis and phenotype, to assess treatment effects and to record safety signals. Implementation of these pragmatic standards should help clinicians to assess the therapy responses of individual patients in clinical practice and improve comparability between observational retrospective studies and controlled prospective trials, supporting future meta-analysis.
AU  - Uhlig, H.H.*
AU  - Booth, C.*
AU  - Cho, J.*
AU  - Dubinsky, M.*
AU  - Griffiths, A.M.*
AU  - Grimbacher, B.*
AU  - Hambleton, S.*
AU  - Huang, Y.*
AU  - Jones, K.*
AU  - Kammermeier, J.*
AU  - Kanegane, H.*
AU  - Koletzko, S.*
AU  - Kotlarz, D.M.
AU  - Klein, C.*
AU  - Lenardo, M.J.*
AU  - Lo, B.*
AU  - McGovern, D.P.B.*
AU  - Ozen, A.*
AU  - de Ridder, L.*
AU  - Ruemmele, F.*
AU  - Shouval, D.S.*
AU  - Snapper, S.B.*
AU  - Travis, S.P.*
AU  - Turner, D.*
AU  - Wilson, D.C.*
AU  - Muise, A.M.*
C1  - 68196
C2  - 54815
CY  - Heidelberger Platz 3, Berlin, 14197, Germany
SP  - 810-828
TI  - Precision medicine in monogenic inflammatory bowel disease: Proposed mIBD REPORT standards.
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 20
IS  - 12
PB  - Nature Portfolio
PY  - 2023
SN  - 1759-5045
ER  - 

TY  - JOUR
AB  - Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.
AU  - Kramvis, A.*
AU  - Chang, K.M.*
AU  - Dandri, M.*
AU  - Farci, P.*
AU  - Glebe, D.*
AU  - Hu, J.*
AU  - Janssen, H.L.A.*
AU  - Lau, D.T.Y.*
AU  - Penicaud, C.*
AU  - Pollicino, T.*
AU  - Testoni, B.*
AU  - Van Bömmel, F.*
AU  - Andrisani, O.*
AU  - Beumont-Mauviel, M.*
AU  - Block, T.M.*
AU  - Chan, H.L.Y.*
AU  - Cloherty, G.A.*
AU  - Delaney, W.E.*
AU  - Geretti, A.M.*
AU  - Gehring, A.*
AU  - Jackson, K.*
AU  - Lenz, O.*
AU  - Maini, M.K.*
AU  - Miller, V.*
AU  - Protzer, U.
AU  - Yang, J.C.*
AU  - Yuen, M.F.*
AU  - Zoulim, F.*
AU  - Revill, P.A.*
C1  - 65765
C2  - 52910
SP  - 727-745
TI  - A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook.
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 19
IS  - 11
PY  - 2022
SN  - 1759-5045
ER  - 

TY  - JOUR
AB  - Cell culture infection models help to develop antiviral agents, but animal models are required to understand complex virus-host interactions and the development of immune therapies. Although identification of the HBV uptake receptor enabled establishing cell lines that replicate HBV from its natural transcription template, animal models supporting the full HBV life cycle are still lacking.
AU  - Protzer, U.
C1  - 50921
C2  - 42965
CY  - New York
SP  - 327-328
TI  - Viral hepatitis: The bumpy road to animal models for HBV infection.
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 14
IS  - 6
PB  - Nature Publishing Group
PY  - 2017
SN  - 1759-5045
ER  - 

TY  - JOUR
AU  - Protzer, U.
C1  - 46697
C2  - 37725
SP  - 558-559
TI  - Epigenetic control of HBV by HBx protein-releasing the break?
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 12
IS  - 10
PY  - 2015
SN  - 1759-5045
ER  - 

TY  - JOUR
AB  - Despite substantial improvements in the diagnosis and treatment of many gastrointestinal cancers, particularly colorectal cancer, numerous patients are only diagnosed in advanced stages of disease, which can preclude curative treatment. Screening and early diagnosis of high-risk individuals might be the most promising approach to improve prognosis; however, molecular biomarkers for early diagnosis of most gastrointestinal cancers are not yet available. The prognosis of patients with advanced gastrointestinal cancers has improved through the development of multimodal treatments and the introduction of targeted therapies. Nonetheless, not all patients benefit equally from these treatment approaches, and toxicity can be substantial. The ability to predict whether a patient will respond to therapy early in their treatment for gastrointestinal cancer may be of particular value to stratify and individualize patient treatment strategies. Despite improvement in the understanding of cancer pathogenesis and progression at the molecular level, the molecular changes that underlie treatment response and/or drug resistance are still largely unknown. PET is the first technique to show promise in prediction of response to therapy, and has resulted in promising advancements, particularly in esophageal and gastric cancers. Tissue-based and blood-based molecular biomarkers are still subject to validation. Prediction of response to treatment could ultimately lead to an overall improvement in prognosis.
AU  - Herrmann, K.*
AU  - Walch, A.K.
AU  - Balluff, B.*
AU  - Tänzer, M.*
AU  - Höfler, H.*
AU  - Krause, B.J.*
AU  - Schwaiger, M.*
AU  - Friess, H.*
AU  - Schmid, R.M.*
AU  - Ebert, M.P.*
C1  - 681
C2  - 26087
SP  - 170-183
TI  - Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.
JO  - Nat. Rev. Gastroenterol. Hepatol.
VL  - 6
IS  - 3
PB  - Nature Publ. Group
PY  - 2009
SN  - 1759-5045
ER  -